JP2012144538A5 - - Google Patents

Download PDF

Info

Publication number
JP2012144538A5
JP2012144538A5 JP2012040759A JP2012040759A JP2012144538A5 JP 2012144538 A5 JP2012144538 A5 JP 2012144538A5 JP 2012040759 A JP2012040759 A JP 2012040759A JP 2012040759 A JP2012040759 A JP 2012040759A JP 2012144538 A5 JP2012144538 A5 JP 2012144538A5
Authority
JP
Japan
Prior art keywords
chemotherapeutic agent
tumor
antagonist
coded
effective amount
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2012040759A
Other languages
English (en)
Japanese (ja)
Other versions
JP5719322B2 (ja
JP2012144538A (ja
Filing date
Publication date
Application filed filed Critical
Publication of JP2012144538A publication Critical patent/JP2012144538A/ja
Publication of JP2012144538A5 publication Critical patent/JP2012144538A5/ja
Application granted granted Critical
Publication of JP5719322B2 publication Critical patent/JP5719322B2/ja
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

JP2012040759A 2004-06-18 2012-02-27 腫瘍の治療 Expired - Lifetime JP5719322B2 (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US58074504P 2004-06-18 2004-06-18
US60/580,745 2004-06-18

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2007516758A Division JP5039544B2 (ja) 2004-06-18 2005-06-17 腫瘍の治療

Publications (3)

Publication Number Publication Date
JP2012144538A JP2012144538A (ja) 2012-08-02
JP2012144538A5 true JP2012144538A5 (enExample) 2013-05-09
JP5719322B2 JP5719322B2 (ja) 2015-05-13

Family

ID=35351719

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2007516758A Expired - Lifetime JP5039544B2 (ja) 2004-06-18 2005-06-17 腫瘍の治療
JP2012040759A Expired - Lifetime JP5719322B2 (ja) 2004-06-18 2012-02-27 腫瘍の治療

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2007516758A Expired - Lifetime JP5039544B2 (ja) 2004-06-18 2005-06-17 腫瘍の治療

Country Status (7)

Country Link
US (2) US8147827B2 (enExample)
EP (1) EP1786466B1 (enExample)
JP (2) JP5039544B2 (enExample)
AU (1) AU2005265067B2 (enExample)
CA (1) CA2570887C (enExample)
ES (1) ES2429041T3 (enExample)
WO (1) WO2006009805A2 (enExample)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6998255B1 (en) * 1999-09-24 2006-02-14 Solvay Pharmaceuticals B.V. Human G-protein coupled receptor
WO2007018316A1 (ja) * 2005-08-09 2007-02-15 Takeda Pharmaceutical Company Limited 癌の予防・治療剤
EA016186B1 (ru) 2005-09-26 2012-03-30 Медарекс, Инк. Человеческие моноклональные антитела к cd70 и их применение
CA2652926A1 (en) * 2006-05-26 2007-12-06 Bayer Healthcare Llc Drug combinations with substituted diaryl ureas for the treatment of cancer
US8535677B2 (en) 2006-06-06 2013-09-17 Oxford Biotherapeutics, Ltd. Antibody drug conjugate treatment of colorectal cancer
WO2008006036A2 (en) * 2006-07-05 2008-01-10 Raven Biotechnologies, Inc. Conditioned cell immunization
WO2008074004A2 (en) * 2006-12-14 2008-06-19 Medarex, Inc. Human antibodies that bind cd70 and uses thereof
EP2093567A1 (en) * 2008-02-21 2009-08-26 Pangaea Biotech, S.A. Brca1 mRNA expression levels predict survival in breast cancer patients treated with neoadjuvant chemotherapy
JP4686733B2 (ja) * 2008-06-02 2011-05-25 国立大学法人 東京大学 抗がん剤
WO2009147781A1 (ja) * 2008-06-02 2009-12-10 国立大学法人東京大学 抗がん剤
JP2011074093A (ja) * 2008-06-02 2011-04-14 Univ Of Tokyo 抗がん剤
WO2009147695A1 (ja) * 2008-06-02 2009-12-10 国立大学法人東京大学 抗がん剤
NZ595792A (en) 2009-04-20 2014-01-31 Oxford Biotherapeutics Ltd Antibodies specific to cadherin-17
US20140086939A1 (en) * 2011-02-28 2014-03-27 Michael Karin Compositions and methods for detecting and treating cancer
JP5771123B2 (ja) * 2011-11-09 2015-08-26 株式会社 資生堂 プロフィラグリンｃ末端ドメイン特異的抗体及びその用途
US9273140B2 (en) * 2012-05-10 2016-03-01 Fujita Health University Antibody for detecting DNA damage in cells utilizing cell membrane surface antigen Ly6D
GB201213652D0 (en) * 2012-08-01 2012-09-12 Oxford Biotherapeutics Ltd Therapeutic and diagnostic target
BR112015026095A8 (pt) 2013-04-15 2020-01-21 Regeneron Pharma método de utilizar biomarcadores responsivos ao tumor, método para seleção de pelo menos uma droga antitumoral, composição compreendendo uma droga antitumoral, combinação para controlar a dosagem de uma droga antitumoral, uso dos biomarcadores responsivos ao tumor
CN105764501A (zh) 2013-07-26 2016-07-13 现代化制药公司 改善比生群治疗效益的组合物
KR102387565B1 (ko) * 2018-11-20 2022-04-18 (주)엠디바이오랩 스트렙토니그린 및 항암제를 모두 포함하는 암 예방 또는 치료용 약학적 조성물

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6831057B2 (en) * 1997-10-28 2004-12-14 The University Of North Carolina At Chapel Hill Use of NF-κB inhibition in combination therapy for cancer
EP2325321A1 (en) 1999-05-28 2011-05-25 THE GOVERNMENT OF THE UNITED STATES OF AMERICA as represented by the SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES A combined growth factor-deleted and thymidine kinase-deleted vaccinia virus vector
JP2003503313A (ja) * 1999-06-03 2003-01-28 ジェシー エル エス オウ 細胞増殖及び細胞死を変調する方法及び組成物
US6652853B2 (en) 2001-03-08 2003-11-25 Ludwig Institute For Cancer Research Method for treating cancer using A33 specific antibodies and chemotherapeutic agents
CA2454648A1 (en) 2001-07-23 2003-02-20 Epidauros Biotechnologie Ag Irinotecan for treatment of cancer
JP2006522163A (ja) 2003-04-07 2006-09-28 グリコジェネシス， インク． ガレクチンアンタゴニストの組成物と使用

Similar Documents

Publication Publication Date Title
JP2012144538A5 (enExample)
HUE049171T2 (hu) Rák diagnózisban felhasználható Claudin 18.2 elleni antitestek
JP2012140442A5 (enExample)
JP2015512729A5 (enExample)
JP2012531046A5 (enExample)
EP3043819A4 (en) Anti-vstm5 antibodies and the use thereof in therapy and diagnosis
BR112014016889A8 (pt) composição sob a forma de uma solução aquosa injetável, sujo ph está compreendido entre 6,0 e 8,0 e, formulação de dose unitária com ph compreendido entre 7 e 7,8
PL2612551T5 (pl) Kompozycja roztoczy zawierająca roztocza drapieżnego i unieruchomiony żer w kontakcie ze środkiem ograniczającym grzyby oraz sposoby i zastosowania dotyczące stosowania wspomnianej kompozycji
JP2014530840A5 (enExample)
EP2858378A4 (en) ULTRASONIC ECHOLOT CONVERTER AND ULTRASONIC FLOWMETER THEREWITH
IL228771A0 (en) Glycoside derivatives and their uses for the treatment of diabetes
Casals et al. Next-generation sequencing approaches for genetic mapping of complex diseases
WO2013188605A3 (en) Predictive markers for cancer and metabolic syndrome
JP2015518492A5 (enExample)
GB201511770D0 (en) Novel pharmaceutical formulationsand their use in the treatment of periodontal disease
JP2014507563A5 (enExample)
JP2012101354A5 (enExample)
JP2010281322A5 (enExample)
IL233875A0 (en) A preparation and its use for the treatment of anal fissures
JP2012179231A5 (enExample)
CL2014003484A1 (es) Uso de nalmefeno en la reduccion del consumo de alcohol en un paciente con dependencia del alcohol; composicion farmaceutica oral; combinacion farmaceutica.
JP2014529579A5 (enExample)
JP2013059750A5 (enExample)
PL3027208T3 (pl) Diagnoza i terapia nowotworu z udziałem nowotworowych komórek macierzystych
Brown et al. MAID.